2C-AL

2C-AL is a drug from the substituted phenethylamine family which acts as an agonist of the 5-HT_2A receptor, with an EC₅₀ of 2.15 nM at 5-HT_2A vs 77.71 nM at 5-HT_2B, and produces a head-twitch response in animal studies. It was first discussed as a hypothetical compound in Daniel Trachsel's 2013 review of the field after his successful synthesis of the related compounds 2C-V and 2C-YN, and finally synthesised by a team at Gilgamesh Pharmaceuticals in 2020 using a different synthetic route from that employed by Trachsel. It is a controlled substance in Canada under phenethylamine blanket-ban language.

See also

• 2C (psychedelics)
• 2C-CP
• 2C-IP
• 2C-P
• 2C-T-16
• 2C-T-TFM
• Allylescaline
• 3C-AL

References